Johnson & Johnson's FY21 COVID-19 Vaccine Sales Below Expectations

Johnson & Johnson JNJ has reported Q4 adjusted earnings of $2.13 per share, up 14.5% Y/Y over the $1.86 posted a year ago and marginally ahead of the consensus of $2.12.

  • Net sales increased 10.4% Y/Y to $24.8 billion, missing the consensus of $25.29 billion.
  • Pharmaceutical contributed $14.29 billion in sales, +16.5%, due to Darzalex (daratumumab), Stelara (ustekinumab), Tremfya (guselkumab), Erleada (apalutamide), and paliperidone palmitate and COVID-19 vaccine.
  • JNJ generated $1.62 billion in COVID-19 vaccine sales during the quarter, compared to $502 million in Q3 FY21.
  • FY21 COVID-19 vaccine sales were $2.38 billion lower than the management expectation of $2.5 billion.
  • The company's Q4 sales from Medical Devices grew 4.1% to $6.85 billion, driven primarily by the market recovery from COVID-19 impacts and the associated deferral of medical procedures.
  • Consumer health segment sales increased 1.1% Y/Y to $3.65 billion, primarily driven by over-the-counter products. 
  • Related: What To Expect When Johnson & Johnson Unveils Q4 Performance This Month.
  • Outlook: Johnson & Johnson expects FY22 total sales of $100.3 billion – $101.8 billion, including $3 billion -3.5 billion from COVID-19 Vaccine sales.
  • It expects adjusted EPS of $10.40 - $10.60, higher than the consensus of $10.37.
  • Price Action: JNJ shares are down 2.59% at $158.75 during the premarket session on the last check Tuesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: BiotechEarningsNewsGuidanceHealth CareMoversTrading IdeasGeneralBriefswhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!